BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, April 16, 2026
Breaking News: Sex differences shape gene activity across the human brainBreaking News: Sex differences shape gene activity across the human brainBreaking News: Best of BioWorld: Q1
Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
BioWorld Science, Infection RSS Feed RSS

Immuno-oncology

KDTV-001: a trivalent HPV vaccine with broad and durable antitumor immunity

April 15, 2026
No Comments
While most human papillomavirus (HPV) infections are cleared by the host immune system, persistent infection with high-risk HPV genotypes, particularly HPV16 and HPV18, can promote cervical cancer development. Researchers from Huazhong University of Science and Technology reported the development and preclinical characterization of KDTV-001, an HPV vaccine comprising a nonreplicating adenovirus type 5 vector encoding a codon-optimized fusion protein of the early antigens E6 and E7 derived from HPV genotypes 16, 18 and 52.
Read More
Infection

The Scripps Research Institute reports new influenza cap-dependent endonuclease inhibitors

April 13, 2026
The Scripps Research Institute has identified new baloxavir analogues and their prodrugs acting as new influenza cap-dependent endonuclease (CEN) inhibitors potentially useful for the treatment of influenza viral infections.
Read More
Coronavirus viral membrane
Infection

ACE2-nanobody fusion enables pan-sarbecovirus neutralization

April 13, 2026
No Comments
SARS-CoV-2 utilizes the angiotensin-converting enzyme 2 (ACE2) receptor for cell entry and triggers ACE2 ectodomain shedding, which results in elevated vasoconstrictor angiotensin II (Ang-II) while depleting the protective Ang-(1-7). This effect can lead to acute respiratory distress syndrome, hypertension, acute kidney injury and organ damage.
Read More
Photo of measles rash on skin
Infection

Invivyd unveils measles monoclonal antibody candidate VMS-063

April 10, 2026
No Comments
Invivyd Inc. has announced the discovery and advancement of VMS-063, a novel monoclonal antibody candidate for the treatment and prevention of measles.
Read More
Infection

Huawu Biopharmaceutical synthesizes new dengue virus replication inhibitors

April 8, 2026
Huawu Biopharmaceutical Technology (Hubei) Co. Ltd. has divulged new viral replication inhibitors potentially useful for the treatment of dengue and yellow fever virus infections.
Read More
Colony of Mucorales grown on petri dish with microscopic illustration
Infection

Dectisomes show potent activity against high-priority fungal pathogens

April 7, 2026
No Comments
In previous work, researchers from the University of Georgia developed liposomes loaded with antifungal drugs and coated with the carbohydrate recognition domains of mouse dectin-1 and/or dectin-2, called Dectisomes. The murine Dectisomes efficiently bound and killed pathogenic fungi in vitro and in mouse disease models. In a new study, the team aimed to explore how to potentially move Dectisomes into the clinic with human dectin orthologues.
Read More
Infection

Wuhan Xirui Pharmaceutical Technology discloses new amphotericin B amide derivatives

April 2, 2026
Wuhan Xirui Pharmaceutical Technology Co. Ltd. has synthesized new amphotericin B amide derivatives that are potentially useful for the treatment of fungal infection.
Read More
Infection

COVID-19 mRNA vaccine provides broad-spectrum protection

April 2, 2026
No Comments
Researchers from the University of Naples Federico II (Italy) and collaborating institutions reportedd the design of a next-generation mRNA vaccine that leverages a phylogenetically informed consensus receptor binding domain heterotrimers representing the major variant lineages.
Read More
Illustration of monoclonal antibody hovering between doctor's hands
Infection

Longhorn reports long-acting peptidoglycan-targeted mAb for sepsis

April 2, 2026
No Comments
At the World Vaccine Congress this week, Longhorn Vaccines & Diagnostics LLC presented the preclinical characterization of LHNVD-501, a half-life-extended, humanized IgG monoclonal antibody (mAb) targeting peptidoglycan (PGN). PGN is a conserved structural component shared across bacterial species and an upstream driver of sepsis, as well as metabolic disease, autoimmune disorders and neurodegeneration.
Read More
Infection

Helmholtz Zentrum München patents compounds for viral infections and cancer

March 27, 2026
Helmholtz Zentrum München Universität Hannover has disclosed new heterocyclic compounds designed for use in the treatment of cancer and viral infection.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 1548 1549 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 15, 2026.
  • MMP inhibitors divulged in Accure Therapeutics patent

    BioWorld Science
    Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 14, 2026
  • Cancer cell in the cross-hairs

    Selective CBL-B inhibitor with improved safety profile disclosed

    BioWorld Science
    CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
  • MSD discloses new HCN1/2 blockers

    BioWorld Science
    Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing